To evaluate dermatological safety of investigational productsby 24 hours patch test under complete occlusion on adulthealthy human subjects with non-sensitive and sensitive skin - NI

Dabur India Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Group 1 Specific:
•Subjects scoring less than or equal to 30 for Section 2- Sensitive v/s Resistant skin
•in modified Dr. Baumannâ??s skin type questionnaire.
•Group 2 Specific:
•Subjects scoring greater than 30 for Section 2- Sensitive v/s Resistant skin in
•modified Dr. Baumannâ??s skin type questionnaire.
•Common to Group 1 & 2:
•1. Healthy male and female subjects (1:1 ratio) in the age group of 18-65 years (both age inclusive).
•2. Subjects representing with normal, oily, dry and combination skin type in equal ratio.
•3. Subjects with normal Fitzpatrick skin type III to V.
•4. Female subjects with child bearing potential willing to undergo Urine Pregnancy Test.
•5. Subjects free from excessive hair, cuts, wounds, irritation symptoms, abrasion or
•any other skin condition which may interfere in the study results.
•6. Subjects willing to give a voluntary written informed consent.
•7. Subjects willing to maintain the patch test in position for 24 hours.
•8. Subject having not participated in a similar investigation in the past two weeks.
•9. Subjects willing to come for regular follow up visits.
•10. Subjects ready to follow instructions during the study period.

•Common to Group 1 & 2:
•1. Infection, allergy on the tested area.
•2. Skin allergy antecedents or atopic subjects.
•3. Subjects with known hypersensitivity to any of the study products or constituents.
•4. Subjects with any significant skin pathology in the investigational area
•5. Athletes and subjects with history of excessive sweating.
•6. Cutaneous disease which may influence the study result.
•7. Subjects using any topical or systemic treatment that could interfere with the
•study treatments/assessments within the last 4 weeks prior to participation in the study and during the study.
•8. Subjects on oral corticosteroid.
•9. Subjects participating in any other cosmetic or therapeutic study.
•10. Female subjects who are pregnant or lactating.
•11. Any history of underlying uncontrolled medical illness including diabetes, liver
•disease or history of alcoholism, HIV or any other serious medical illness

发起方